Lymphoma Clinical Trials in North Carolina

Showing 281-300 of 647 trials

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

NCT02168140

This phase I trial studies the side effects and best dose of CPI-613 when given together with bendamustine hydrochloride in treating patients with relapsed or refractory T-cell non-Hodgkin lymphoma or Hodgkin lymphoma. CPI-613 may kill cancer cells by turning off their mitochondria, which are used by cancer cells to produce energy and are the building blocks needed to make more cancer cells. By shutting off mitochondria, CPI-613 may deprive the cancer cells of energy and other supplies needed to survive and grow. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving CPI-613 with bendamustine hydrochloride may kill more cancer cells.

Adult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin Lymphoma+14 more

Wake Forest University Health Sciences16 participantsStarted Sep 2014

Winston-Salem, North Carolina, United States • Philadelphia, Pennsylvania, United States

COMPLETED57 miles

Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

NCT01000753

This research study is collecting and storing tissue samples from patients with rare or cutaneous non-Hodgkin lymphoma. Collecting and storing samples of tissue from patients with cancer to test in the laboratory may help the study of cancer in the future.

Adult Immunoblastic LymphomaCentral Nervous System Non-Hodgkin LymphomaChildhood Immunoblastic Lymphoma+10 more

Children's Oncology Group174 participantsStarted May 2005

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Phoenix, Arizona, United States +127 more locations

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

Lymphoma Trials in Other Cities

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma

A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

ALPN-202 With PD-1 Inhibition in Advanced Malignancies

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)

A Study of BTX-1188 in Subjects With Advanced Malignancies

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Other Conditions in North Carolina